PHARMASPIRE - Volume 15, Issue 03, 2023 , July- September

Pages: 177-183

Date of Publication: 11-Dec-2023

Print Article   Download XML  Download PDF

Type 2 diabetes mellitus-associated cognitive impairment and management.

Author: Priyanka Swarnkar, Prabha Rajput

Category: Pharmacology

Abstract:

Diabetes mellitus (DM) is a complex metabolic condition characterized by persistent hyperglycemia and poor metabolism due to insulin production irregularities and/or insulin resistance type 2 DM (T2DM) and dementia are linked through a variety of methods. Thus, in terms of the long-term repercussions of diabetes, the current idea focuses on cognitive damage, the exact pathophysiology of which is unknown. A new term, “diabetes-associated cognitive decline,” has recently been proposed to aid study in this field. This review discusses how different variables contribute to the development of T2DM. Furthermore, we investigated an expanding body of literature on insulin signaling in diabetics, as well as various factors such as insulin resistance, hyperglycemia, neuroinflammation, and Aβ (amyloid beta) plaques that may act alone or in combination to link T2DM with cognitive impairments. Finally, we looked at how physical activity and a balanced diet might help fight the condition.

Keywords: Dementia, Diabetes mellitus, Hyperglycemia, Insulin resistance, Neuroinflammation

DOI: 10.56933/Pharmaspire.2023.15128

DOI URL: https://doi.org/10.56933/Pharmaspire.2023.15128

References:

1. Ruiz-Alejos A, Carrillo-Larco RM, Miranda JJ, Anderson CA, Gilman RH, Smeeth L, et al. Addressing the impact of urban exposure on the incidence of Type 2 diabetes mellitus: The PERU MIGRANT study. Sci Rep 2018;8:5512.

2. Cantley J, Ashcroft FM. Q&A: Insulin secretion and Type 2 diabetes: Why do β-cells fail? BMC Biol 2015;13:33.

3. Arnold SE, Arvanitakis Z, Macauley-Rambach SL, Koenig AM, Wang HY, Ahima RS, et al. Brain insulin resistance in Type 2 diabetes and Alzheimer disease: Concepts and conundrums. Nat Rev Neurol 2018;14:168-81.

4. Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, et al. The diabetic brain and cognition. J Neural Transm (Vienna) 2017;124:1431-54.

5. Wondmkun YT. Obesity, insulin resistance, and Type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes 2020;13:3611-6.

6. Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes 2014;7:587-91.

7. Gorelick PB, Furie KL, Iadecola C, Smith EE, Waddy SP, Lloyd-Jones DM, et al. Defining optimal brain health in adults: A presidential advisory from the American Heart Association/American Stroke Association. Stroke 2017;48:e284-303.

8. Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer’s disease a Type 3 diabetes? A critical appraisal. Biochim Biophys Acta Mol Basis Dis 2017;1863:1078-89.

9. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet 2017;390:2673-34.

10. Groeneveld O, Reijmer Y, Heinen R, Kuijf H, Koekkoek P, Janssen J, et al. Brain imaging correlates of mild cognitive impairment and early dementia in patients with Type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis 2018;28:1253-60.

11. Biessels GJ, Strachan MW, Visseren FL, Kappelle LJ, Whitmer RA. Dementia and cognitive decline in Type 2 diabetes and prediabetic stages: Towards targeted interventions. Lancet Diabetes Endocrinol 2014;2:246-55.

12. Stephan BC, Pakpahan E, Siervo M, Licher S, MunizTerrera G, Mohan D, et al. Prediction of dementia risk in low-income and middle-income countries (the 10/66 Study): An independent external validation of existing models. Lancet Glob Health 2020;8:e524-35.

13. Ferri CP, Guerchet M, Prince M. Global challenge of dementia: What can be done? In: Dementia. CRC Press; 2017. p. 408-21.

14. Angeles-Agdeppa I, Custodio MR. Food sources and nutrient intakes of filipino working adults. Nutrients 2020;12:1009.

15. Bhat ZF, Morton JD, Mason S, Bekhit AE, Bhat HF. Obesity and neurological disorders: Dietary perspective of a global menace. Crit Rev Food Sci Nutr 2019; 59:1294-310.

16. Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, et al. Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: Update and areas of immediate need. Alzheimers Dement 2019;15:292-312.

17. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer’s disease and vascular dementia in developing countries: Prevalence, management, and risk factors. Lancet Neurol 2008;7:812-26.

18. Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer’s and vascular types. Biomed Res Int 2014;2014:9089.

19. Soumya D, Srilatha B. Late stage complications of diabetes and insulin resistance. J Diabetes Metab 2011;2:1000167.

20. Petersen MC, Shulman GI. Mechanisms of insulin action and insulin resistance. Physiol Rev 2018;98:2133-223.

21. Potenza MA, Sgarra L, Desantis V, Nacci C, Montagnani M. Diabetes and Alzheimer’s disease: Might mitochondrial dysfunction help deciphering the common path? Antioxidants (Basel) 2021;10:1257.

22. Liu SL, Wang C, Jiang T, Tan L, Xing A, Yu JT. The role of Cdk5 in Alzheimer’s disease. Mol Neurobiol 2016;53:4328-42.

23. Ruud J, Steculorum SM, Brüning JC. Neuronal control of peripheral insulin sensitivity and glucose metabolism. Nat Commun 2017;8:15259.

24. Lukinovi-Škudar V, ?ermanovi? Dobrota V, Šimi? G. Common pathogenetic factors in metabolic syndrome and dementia. Rad Hrvatske akademije znanosti i umjetnosti. Medicinske znanosti 553. 2022;60-61:74-83.

25. Capucho AM, Chegão A, Martins FO, Vicente Miranda H, Conde SV. Dysmetabolism and neurodegeneration: Trick or treat? Nutrients 2022;14:1425.

26. Hurtado DE. Selective Reduction of GSK-3 Isoforms Ameliorates Pathological Signatures of Alzheimer’s Disease. Philadelphia, PA: University of Pennsylvania; 2011.

27. Huat TJ, Camats-Perna J, Newcombe EA, Valmas N, Kitazawa M, Medeiros R. Metal toxicity links to Alzheimer’s disease and neuroinflammation. J Mol Biol 2019;431:1843-68.

28. Zhang Y, Huang NQ, Yan F, Jin H, Zhou SY, Shi JS, et al. Diabetes mellitus and Alzheimer’s disease: GSK-3β as a potential link. Behav Brain Res 2018;339:57-65.

29. Ittner A, Chua SW, Bertz J, Volkerling A, van der Hoven J, Gladbach A, et al. Site-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice. Science 2016;354:904-8.

30. Kent SA, Spires-Jones TL, Durrant CS. The physiological roles of tau and Aβ: Implications for Alzheimer’s disease pathology and therapeutics. Acta Neuropathol 2020;140:417-47.

31. Jiang H, Liu J, Guo S, Zeng L, Cai Z, Zhang J, et al. miR-23b-3p rescues cognition in Alzheimer’s disease by reducing tau phosphorylation and apoptosis via GSK-3β signaling pathways. Mol Ther Nucleic Acids 2022;28:539-57.

32. Mitsea E, Drigas A, Skianis C. Breathing, attention & consciousness in sync: The role of breathing training, metacognition & virtual reality. Technium Soc Sci J 2022;29:79-97.

33. Plahay T. Yoga for Dementia: A Guide for People with Dementia, their Families and Caregivers. United States: Jessica Kingsley Publishers; 2018.

34. Izquierdo M, Merchant RA, Morley JE, Anker SD, Aprahamian I, Arai H, et al. International exercise recommendations in older adults (ICFSR): Expert consensus guidelines. J Nutr Health Aging 2021;25:824-53.

35. Wang B, Wang N, Sun Y, Tan X, Zhang J, Lu Y. Association of combined healthy lifestyle factors with incident dementia in patients with Type 2 diabetes. Neurology 2022;99:e2336-45.

36. Santoro A, Ostan R, Candela M, Biagi E, Brigidi P, Capri M, et al. Gut microbiota changes in the extreme decades of human life: A focus on centenarians. Cell Mol Life Sci 2018;75:129-48.

37. Lange KW, Guo J, Kanaya S, Lange KM, Nakamura Y, Li S. Medical foods in Alzheimer’s disease. Food Sci Hum Wellness 2019;8:1-7.

38. McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: Links to socioeconomic status, health, and disease. Ann N Y Acad Sci 2010;1186:190-222.

39. Scarmeas N, Anastasiou CA, Yannakoulia M. Nutrition and prevention of cognitive impairment. Lancet Neurol 2018;17:1006-15.

40. Colbert D. Reversing Diabetes: Discover the Natural Way to Take Control of Type 2 Diabetes. Florida: Charisma Media; 2012.

41. Raveendran AV, Deshpandae A, Joshi SR. Therapeutic role of yoga in Type 2 diabetes. Endocrinol Metab (Seoul) 2018;33:307-17.

42. Suryawanshi VD, Deshpande VP, Patrikar VV. Effect of yogasana and pranayama as a preventive aspect of medovaha and mutravaha strotas in diabetes mellitus: A review. World J Pharm Res 2019;9:945-51.

43. Fort K. Effect of short-term practice of bhramari pranayama on sleep quality and perceived stress in school students. Int J Physiol 2021;9:1-6.

44. Govindaraj R, Karmani S, Varambally S, Gangadhar BN. Yoga and physical exercise - a review and comparison. Int Rev Psychiatry 2016;28:242-53.

45. Markowicz-Piasecka M, Sikora J, Szyd?owska A, Skupie? A, Mikiciuk-Olasik E, Huttunen KM. Metformin - a future therapy for neurodegenerative diseases: Theme: Drug discovery, development and delivery in Alzheimer’s disease guest editor: Davide Brambilla. Pharm Res 2017;34:2614-27.

46. Ghosh RK, Ghosh GC, Gupta M, Bandyopadhyay D, Akhtar T, Deedwania P, et al. Sodium glucose co-transporter 2 inhibitors and heart failure. Am J Cardiol 2019;124:1790-6.

47. Song MK, Bischoff DS, Song AM, Uyemura K, Yamaguchi DT. Metabolic relationship between diabetes and Alzheimer’s disease affected by Cyclo (His-Pro) plus zinc treatment. BBA Clin 2017;7:41-54.

48. Tyagi A, Pugazhenthi S. Targeting insulin resistance to treat cognitive dysfunction. Mol Neurobiol 2021;58:2672-91.

49. Liu KY, Howard R. Can we learn lessons from the FDA’s approval of aducanumab? Nat Rev Neurol 2021;17:715-22.